Richard Guillaume

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA.

Delta Dore SA develops technologies in the field of energy management, security and control systems. The firm offers various types of heating management products including energy managers, programmers, consumption indicators, programmable thermostats, sensors, controllers, and peripheral equipment. It also offers various types of security products including control units, detectors, sirens, telephone transmitters, remote controls, and accessories. The company was founded by Monique and Joel Renault in 1970 and is headquartered in Bonnemain, France.

Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector.

Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France.

Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US.

Vertex manufactures optical materials. The company is located in ZA du Boulais, South Africa.

Hollister, Inc. develops, manufactures and markets healthcare products and services. Its products include Ostomy, continence, wound, skin and critical care products. The company was founded by John Dickinson Schneider in 1921 and is headquartered in Libertyville, IL.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

GO Capital SAS (GO Capital) is an independent French private equity firm founded 2003 and is headquartered in Saint-Jacques-de-la-Lande. Formerly known as Grand Ouest Gestion SAS, the firm's investors include regional and cooperative banks, Natixis and CDC PME.GO Capital is located in Rennes and focuses primarily on the northwest quarter of France, also known as Grand Ouest, which comprises the Brittany, Poitou-Charentes, Pays de la Loire and Basse Normandie regions. The firm manages the Ouest Ventures fund.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

Bretagne Jeunes Entreprises SA (BJE) is an independent French venture capital firm which was created in 1999 by la Région Bretagne and CDC Enterprises. to help invest in start-ups located in the Britanny region of France. Based in Rennes, BJE's shareholders include four regional banks (Banque populaire de l'Ouest, Crédit Mutuel de Bretagne, Caisse d'épargne Bretagne-Pays de Loire, Crédit Agricole) and OSEO Bretagne.

Delta Dore Finance functions as an investment holding firm. The company is headquartered in Bonnemain, France.

Part of ResMed, Inc., ResMed Medizintechnik GmbH is a medical device manufacturer. The company is based in Gremsdorf, Germany. The German company was founded in 1993. The CEO is Anne Reiser.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

VALKEE Oy develops and manufactures health devices. Its flagship product Valkee is a pocket-sized light therapy device that channels bright light via the ear canals into the brain that has beneficial effects on mood and wellbeing of people. The firm is carrying out additional tests and studies concerning the effects of bright light on cognitive and physical performance and jet lag. The company was founded by Juuso Samuel Nissilä and Antti Aunio in 2007 and is headquartered in Oulu, Finland.

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Les Nouvelles Éditions Indépendantes SASU operates as a holding company, with interest in newspaper publishing. The company was founded on July 27, 2009 and is headquartered in Paris, France.

keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel.

Rythm SAS develops a device which helps to monitor and analyze the sleep. Its product, Dreem, is a sleep solution that monitors, analyzes, and acts on brain to enhance sleep. The company was founded by Hugo Mercier and Quentin Soulet de Brugière in 2014 and is headquartered in Paris, France.

Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation.

Part of Sera SAS, Advanced Data Wireless Network SAS is a French company that provides wireless network integration solutions. The company is based in Decines Charpieu, France. The company was founded in 2003 by Jérôme Bernard. The CEO is Stéphane Dugas. Advanced Data Wireless Network was acquired by Sera SAS on September 05, 2023.